Glide Technologies has extended its contract extension for the advancement of an alternative delivery method for Pfenex's recombinant protective antigen, Px563L-mrPA, using Glide solid dose formulation technology. This contract continuation is the result of the National Institute of Allergy and Infectious Diseases (NIAID) exercising its first contract option under its existing contract with Pfenex.

Source Glide Technologies